Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Eton Pharmaceuticals (Nasdaq: ETON), a pharmaceutical company focused on rare disease treatments, has scheduled its third quarter 2024 financial results announcement for Tuesday, November 12, 2024. Management will host a conference call and audio webcast at 4:30 p.m. ET to discuss the results. The company will take live questions during the call and answer emailed investor questions sent to investorrelations@etonpharma.com. The webcast will be accessible through Eton's investor relations website and will remain available for 30 days after the event.
Eton Pharmaceuticals (Nasdaq: ETON), un'azienda farmaceutica focalizzata sui trattamenti per malattie rare, ha programmato l'annuncio dei suoi risultati finanziari del terzo trimestre 2024 per marted矛 12 novembre 2024. La direzione ospiter脿 una conference call e un webcast audio alle 16:30 ET per discutere i risultati. L'azienda accetter脿 domande in diretta durante la chiamata e risponder脿 alle domande degli investitori inviate via email a investorrelations@etonpharma.com. Il webcast sar脿 accessibile tramite il sito web per le relazioni con gli investitori di Eton e rimarr脿 disponibile per 30 giorni dopo l'evento.
Eton Pharmaceuticals (Nasdaq: ETON), una compa帽铆a farmac茅utica enfocada en tratamientos para enfermedades raras, ha programado el anuncio de sus resultados financieros del tercer trimestre de 2024 para el martes 12 de noviembre de 2024. La gerencia llevar谩 a cabo una llamada de conferencia y una transmisi贸n de audio a las 4:30 p.m. ET para discutir los resultados. La empresa aceptar谩 preguntas en vivo durante la llamada y responder谩 a las preguntas de los inversores enviadas por correo electr贸nico a investorrelations@etonpharma.com. La transmisi贸n estar谩 disponible a trav茅s del sitio web de relaciones con inversores de Eton y permanecer谩 accesible durante 30 d铆as despu茅s del evento.
Eton Pharmaceuticals (Nasdaq: ETON)電� 頋穩 歆堩櫂 旃橂鞐� 欷戩爯鞚� 霊� 鞝滌暯 須岇偓搿�, 2024雲� 3攵勱赴 鞛 瓴瓣臣 氚滍憸毳� 2024雲� 11鞗� 12鞚� 頇旍殧鞚茧 鞓堨爼頃橃榾鞀惦媹雼�. 瓴届榿歆勳潃 瓴瓣臣毳� 雲检潣頃橁赴 鞙勴暣 霃欕秬鞁滉皠 旮办 鞓ろ泟 4鞁� 30攵勳棎 旎嵓霟办姢 旖� 氚� 鞓る敂鞓� 鞗轨簮鞀ろ姼毳� 臧滌禍頃╇媹雼�. 須岇偓電� 韱淀檾 欷� 鞁れ嫓臧� 歆堧鞚� 氚涥碃, investorrelations@etonpharma.com鞙茧 氤措偞歆� 鞚措⿺鞚� 韴瀽鞛� 歆堧鞐� 雼惦硛頃� 瓴冹瀰雼堧嫟. 鞗轨簮鞀ろ姼電� Eton鞚� 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼毳� 韱淀暣 鞝戧芳 臧�電ロ晿氅�, 頄夓偓 頉� 30鞚� 霃欖晥 鞚挫毄頃� 靾� 鞛堨姷雼堧嫟.
Eton Pharmaceuticals (Nasdaq: ETON), une entreprise pharmaceutique sp茅cialis茅e dans les traitements des maladies rares, a pr茅vu d'annoncer ses r茅sultats financiers du troisi猫me trimestre 2024 le mardi 12 novembre 2024. La direction organisera une conf茅rence t茅l茅phonique et un webinaire audio 脿 16h30 ET pour discuter des r茅sultats. L'entreprise prendra des questions en direct pendant l'appel et r茅pondra aux questions des investisseurs envoy茅es par e-mail 脿 investorrelations@etonpharma.com. Le webinaire sera accessible via le site web des relations avec les investisseurs d'Eton et restera disponible pendant 30 jours apr猫s l'茅v茅nement.
Eton Pharmaceuticals (Nasdaq: ETON), ein auf Behandlungen seltener Krankheiten fokussiertes Pharmaunternehmen, hat die Bekanntgabe seiner Finanzergebnisse f眉r das dritte Quartal 2024 auf Dienstag, den 12. November 2024, festgelegt. Das Management wird um 16:30 Uhr ET eine Telefonkonferenz und ein Audio-Webcast abhalten, um die Ergebnisse zu besprechen. Das Unternehmen wird w盲hrend des Anrufs Live-Fragen entgegennehmen und Antworten auf per E-Mail gesendete Investorenfragen an investorrelations@etonpharma.com geben. Der Webcast wird 眉ber die Investor-Relations-Website von Eton zug盲nglich sein und 30 Tage nach der Veranstaltung verf眉gbar bleiben.
- None.
- None.
DEER PARK, Ill., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (鈥淓ton鈥� or the "Company鈥�) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).
| Dial in (Audio Only) | 听 | Toll-free: 888-596-4144 |
| 听 | 听 | Non-toll free: 646-968-2525 |
| 听 | 听 | Access Code: 1144771 |
| 听 | 听 | 听 |
| Webcast: | 听 | |
| 听 | 听 | 听 |
In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: .
The live webcast can also be accessed on the Investors section of Eton鈥檚 website at . An archived webcast will be available on Eton鈥檚 website approximately two hours after the completion of the event and for 30 days thereafter.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has five commercial rare disease products: ALKINDI SPRINKLE庐, PKU GOLIKE庐, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO庐 hydrocortisone autoinjector. For more information, please visit our website at听.
Investor Relations:
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E:
Source: Eton Pharmaceuticals, Inc.
FAQ
When will Eton Pharmaceuticals (ETON) report Q3 2024 earnings?
What time is Eton Pharmaceuticals (ETON) Q3 2024 earnings call?
How can investors participate in Eton Pharmaceuticals (ETON) Q3 2024 earnings call?
